Communiqués PeptiDream Inc.

Actions

4587

JP3836750004

Recherche biotechnologique et médicale

Temps Différé Japan Exchange 07:33:27 01/10/2026			Varia. 5j.	Varia. 1 janv.
1 136,50 ^JPY	+2,07%		+7,57%	-31,39%

12/08	PeptiDream franchit une étape clé avec le lancement par Novartis d'un essai de phase 1 en oncologie	MT
12/08	PeptiDream Inc. publie ses résultats pour le premier semestre clos le 30 juin 2026	CI

Communiqués

11/09	PeptiDream : Sustainability Impact Report 2026(13.4 MB)	PU
02/07	PeptiDream Strengthens Leadership Team with Multiple Key Executive Appointments	BU
11/06	PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer	BU
11/06	PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan	BU
11/06	Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan	AQ
20/04	PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner	BU
19/12	Script: Q&A Session on the R&D Briefing(December 5, 2025)	PU
18/12	PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues	BU
17/12	PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis	BU
05/12	PeptiDream : R&D Briefing Materials (December 5, 2025)	PU
16/10/25	Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan	AQ
15/10/25	PeptiDream, PDRadiopharma and Curium Group Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan	BU
16/05/25	PeptiDream : Corporate Overview（May 2025)	PU
31/03/25	National Cancer Center Japan and PeptiDream: New Radiopharmaceuticals for Renal Cell Carcinoma	AQ
28/03/25	National Cancer Center Japan and PeptiDream: New Radiopharmaceuticals for Renal Cell Carcinoma	BU
26/03/25	PeptiDream : Management Briefing Materials (March 27, 2025)	PU
21/02/25	PeptiDream : Corporate Overview（February 2025)	PU
14/12/24	PeptiDream : R&D Briefing Materials (December 12, 2024)	PU
12/12/24	PeptiDream Announces Second Internal Peptide Radiopharmaceutical Therapeutic Program Targeting Claudin 18.2 for the Potential Diagnosis and Treatment of Gastric Cancer	BU
12/12/24	PeptiDream Announces Preclinical Results Demonstrating Efficacy of Oral Myostatin Inhibitors in Preventing Loss of Lean Mass Associated with Semaglutide Treatment	BU
05/12/24	NorthStar Medical Radioisotopes and PDRadiopharma Announce Research and Development Agreement, Master Isotope Supply Agreement for Ac-225 and Contract Manufacturing and Master Services Agreement	BU
01/10/24	PeptiDream : Corporate Overview（October 2024, English version)	PU
30/08/24	PeptiDream : Sustainability Report 2024(3.6 MB)	PU
01/07/24	PeptiDream : Corporate Overview（July 2024, English version)	PU
04/06/24	NCC and PeptiDream Announce the First Dosing of 64Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma	BU